1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. Key Findings of the Study
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. Middle East and Africa Over-the-Counter Market Forecast by Product Category (US$ Billion)
5.1. Introduction
5.2. Cough, Cold and flu products
5.3. Analgesics
5.4. Dermatology products
5.5. Gastrointestinal products
5.6. Vitamins, mineral and supplements (VMS)
5.7. Weight loss/Dietary products
5.8. Ophthalmic Products
5.9. Sleep Aids
5.10. Others
6. Middle East and Africa Over-the-Counter Market Forecast by Administration (US$ Billion)
6.1. Introduction
6.2. Oral
6.3. Topical
6.4. Parenteral
7. Middle East and Africa Over-the-Counter Market Forecast by Geography (US$ Billion)
7.1. Introduction
7.2. Middle East and Africa
7.2.1. UAE
7.2.2. Israel
7.2.3. Qatar
7.2.4. Others
8. Competitive Intelligence
8.1. Strategies of Key Players
8.2. Recent Investments and Deals
9. Company Profiles
9.1. Covance, Inc.
9.1.1. Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Key Developments
9.2. Johnson and Johnson
9.2.1. Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Key Developments
9.3. Novartis AG
9.3.1. Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Key Developments
9.4. Bayer AG
9.4.1. Overview
9.4.2. Financials
9.4.3. Products and Services
9.4.4. Key Developments
9.5. Sanofi
9.5.1. Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Key Developments
9.6. Pfizer, Inc.
9.6.1. Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Key Developments
9.7. GlaxoSmithKline plc.
9.7.1. Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Key Developments
9.8. Boehringer Ingelheim GmbH
9.8.1. Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Key Developments
9.9. PGT healthcare
9.9.1. Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Key Developments
9.10. Takeda Pharmaceutical Company Limited
9.10.1. Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Key Developments
List of Tables
List of Figures